FDA Agrees to Consider Moderna’s mRNA Influenza Vaccine

‘We look forward to making our flu vaccine available later this year,’ Moderna CEO Stephane Bancel said.

The Moderna campus in Norwood, Mass., on Dec. 2, 2020. Joseph Prezioso/AFP via Getty Images

The Food and Drug Administration has agreed to review a revised application from Moderna for its experimental influenza vaccine.

Moderna executives and FDA officials recently held a meeting, and after discussing the FDA’s recent refusal to consider an application for approval of the flu shot, Moderna filed an amended application.